5-Aza-2'-Deoxycytidine
3 Inquiries
2353-33-5
Pharmaceutical Grade
99%
Any China Port
1kg/as customer's requirment
2020-06-29
API,Intermediate
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceDecitabine (NSC 127716) is a DNA methyltransferase inhibitor commonly used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
5-aza-2'-deoxycytidine is a fine white crystalline powder. Used as a drug.|Solid
5-aza-2'-deoxycytidine is a fine white crystalline powder. Used as a drug.|5-aza-2'-deoxycytidine is a 2'-deoxyribonucleoside.|Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment options, nucleoside analogues such as decitabine and [azacitidine] integrate into cellular DNA and inhibit the action of DNA methyltransferases, leading to global hypomethylation and related downstream therapeutic benefits. Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. It was first marketed under the name Dacogen®. It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine].|Decitabine is a Nucleoside Metabolic Inhibitor. The mechanism of action of decitabine is as a Nucleic Acid Synthesis Inhibitor.|Decitabine is a cytosine analogue and an intravenously administered antineoplastic agent used in the therapy of myelodysplastic syndromes. Decitabine is associated with a low rate of transient serum enzyme elevations during therapy, but has not been implicated in causing clinically apparent liver injury with jaundice.|Decitabine is a cytidine antimetabolite analogue with potential antineoplastic activity. Decitabine incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. (NCI04)|An azacitidine derivative and antineoplastic antimetabolite. It inhibits DNA methyltransferase to re-activate silent genes, limiting METASTASIS and NEOPLASM DRUG RESISTANCE. Decitabine is used in the treatment of MYELODISPLASTIC SYNDROMES, and ACUTE MYELOID LEUKEMIA.Basic Info-
Product Name:
5-Aza-2′-deoxycytidine
Other Name:1,3,5-Triazin-2(1H)-one,4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-;s-Triazin-2(1H)-one,4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-;4-Amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one;5-Aza-2′-deoxycytidine;5-Azadeoxycytidine;2-Desoxy-5-azacytidine;2′-Deoxy-5-azacytidine;Decitabine;NSC 127716;DAC;Dacogen;β-Decitabine;5-Aza-2-deoxycytidine;4-Amino-1-(2-deoxy-β-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one;A 2232;NSC127716;105597-46-4;123795-43-7
CAS No.:2353-33-5
Molecular Formula:C8H12N4O4
InChIKeys:InChIKey=XAUDJQYHKZQPEU-KVQBGUIXSA-N
Molecular Weight:228.21
Exact Mass:228.21
EC Number:219-089-4
UNII:776B62CQ27
DSSTox ID:DTXSID7030432
NCI Thesaurus Code:C981
ATC Code:L01BC08|L - Antineoplastic and immunomodulating agents
HScode:29349990
Categories:
Characteristics-
PSA:
121
XLogP3:-1.2
Appearance:White to Off-white Powder
Density:1.9±0.1 g/cm3
Melting Point:198-199 °C (decomp)
Boiling Point:485.8°C at 760 mmHg
Flash Point:247.6±31.5 °C
Refractive Index:1.780
Water Solubility:acetic acid/water (1:1): 50 mg/mL
Storage Conditions:−20°C
Vapor Pressure:1.78E-11mmHg at 25°C
Toxicity:Intravenous-mouse LD50: 22 mg/kg; Intraperitoneal-mouse LD50: 190 mg/kg
Flammability characteristics:Flammable; burning produces toxic nitrogen oxide fumes
Specific rotation:D22 +68.5° (30 min)+57.8° (6 hr) (c = 0.5 in water)
Air and Water Reactions:Probably light and air sensitive. Water soluble. Decomposes in aqueous solution at a rate that depends on pH: at pH 7 the drug is more stable than at pH 9, but is less stable than at pH 6. At pH 7 and 99°F, approximately 7% conversion occurs in 1 hour (NTP, 1992).
Reactive Group:Alcohols and Polyols
Reactivity Profile:5-AZA-2'-DEOXYCYTIDINE is an organic compound with both amine and alcohol substituents. Amines are chemical bases. They neutralize acids to form salts plus water. These acid-base reactions are exothermic. The amount of heat that is evolved per mole of amine in a neutralization is largely independent of the strength of the amine as a base. Amines may be incompatible with isocyanates, halogenated organics, peroxides, phenols (acidic), epoxides, anhydrides, and acid halides. Flammable gaseous hydrogen is generated by amines in combination with strong reducing agents, such as hydrides.
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Skin irritation, Category 2
Eye irritation, Category 2
Specific target organ toxicity â single exposure, Category 3
Germ cell mutagenicity, Category 2
Reproductive toxicity, Category 1B
GHS label elements, including precautionary statements
Pictogram(s) 
Signal word Danger
Hazard statement(s) H302 Harmful if swallowed
H315 Causes skin irritation
H319 Causes serious eye irritation
H335 May cause respiratory irritation
H341 Suspected of causing genetic defects
H360 May damage fertility or the unborn child
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P271 Use only outdoors or in a well-ventilated area.
P203 Obtain, read and follow all safety instructions before use.
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P302+P352 IF ON SKIN: Wash with plenty of water/...
P321 Specific treatment (see ... on this label).
P332+P317 If skin irritation occurs: Get medical help.
P362+P364 Take off contaminated clothing and wash it before reuse.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P319 Get medical help if you feel unwell.
P318 IF exposed or concerned, get medical advice.
Storage P403+P233 Store in a well-ventilated place. Keep container tightly closed.
P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Distributor
-
Main Products:
API,Intermediate
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
30
-
Total Annual Revenue:
Above $100 million
-
Total Employees:
201-300
About Echemi Pharmaceutical
Echemi’s philosophy is to seek for higher quality, to explore frontier area. The progress of human society, the extension of life expectancy, and the conquest of disease are all derived from the numerous businesses and individuals who have quietly dedicated themselves in the pharmaceutical industry. It’s the controlling of supply chain quality that ensures the efficacy. It’s the continuous exploration that promotes the development of the pharmaceutical industry and benefits more future generations. The pursuit of high quality requires all partners of Echemi Pharmaceutical to be screened, whether its certificate, qualification or scale. In the field of renewal, we will embrace all new changes and make more contributions to the development of pharmaceutical industry.
Advantage for Pharmaceutical
• Having been working in pharmaceutical field for more then 15 years, we have experienced regulatory team, quality control team, sourcing team, technical support team, and logistics team. And we are familiar with the regulatory requirements from different areas, can offer tailored service for our customers.
• We have hundreds of strategic partners for APIs, intermediates, and custom synthesis. All of our partners are ready to support our customers with documents, and be audited.
• We can offer custom synthesis for some new chemical structures and some materials which there are no reliable suppliers.
Product Category
We care for human and animal health and we are committed to creating a better social environment.
• Human API
• Intermediate
• Veterinary API
• Agrochemical
• Fine Chemical
• Custom Synthesis
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted 
United Kingdom
decitabine
500 MG May 3, 2026 
United States
decitabine
1 G Apr 27, 2026
United States
5-aza-2′-deoxycytidine
1 G Aug 1, 2026 Post an enquiry for this product